Download
In the ever-evolving landscape of private equity, exits are not merely transactions—they are strategic statements. CVC Capital Partners’ reported exploration of selling its 22.5% stake in Soho Global Health (SGH), an Indonesian healthcare company, underscores a pivotal moment in the lifecycle of emerging market investments. This potential exit, which could value SGH at $650 million, reflects broader trends in private equity value realization, the maturation of Southeast Asian healthcare markets, and the shifting calculus of institutional investors in a post-pandemic world.
The Strategic Rationale Behind CVC’s Exit
CVC’s stake in Soho Global, acquired in 2020 from Quadria Capital, has been a high-conviction bet on Indonesia’s consumer health sector. SGH’s portfolio—encompassing brands like Curcuma Plus (a turmeric-based supplement) and Imboost (a vitamin C-rich product)—has benefited from rising health consciousness and disposable incomes in Southeast Asia. The company’s 2024 financials, including a net income of 463 billion rupiah ($27.6 million) and revenue of 10 trillion rupiah ($698 million), highlight its operational resilience.
CVC’s potential sale of up to a 51% controlling stake signals a calculated move to crystallize value. At a 2025 market valuation of $527 million, SGH’s price-to-earnings (P/E) ratio of ~18x (based on 2024 earnings) aligns with regional healthcare benchmarks. This premium reflects investor appetite for companies with strong EBITDA margins and scalable distribution networks—key attributes SGH has cultivated through its partnerships with pharmacies and digital health platforms.
Broader Trends: PE Exits in Southeast Asian Healthcare
CVC’s exit must be contextualized within the broader revival of private equity in Southeast Asia. In 2024, the region saw double-digit growth in exit value and count, driven by secondary transactions rather than IPOs. Healthcare, in particular, accounted for 27% of PE-backed investments in Q2 2025, with Singapore and Vietnam dominating deal activity. This trend is no accident: the sector’s growth is fueled by aging populations, rising chronic disease prevalence, and digital transformation in healthcare delivery.
Secondary exits have become a preferred route for liquidity, especially as IPO markets remain muted. For instance, the 2024 PropertyGuru exit—a $1.1 billion secondary deal—highlighted the region’s shift toward strategic sales to institutional buyers. This aligns with CVC’s approach, as selling to a buyer with operational expertise (e.g., a regional healthcare conglomerate or a global PE firm) could maximize SGH’s value while preserving its growth trajectory.
The Attractiveness of Southeast Asian Consumer Health
Southeast Asia’s healthcare sector is a compelling case study in demographic and economic tailwinds. Indonesia, SGH’s core market, has a population of 275 million, with a rapidly expanding middle class. The World Bank projects that Indonesia’s healthcare expenditure will grow at a 9% CAGR through 2030, driven by urbanization and rising health awareness. For institutional investors, this represents a long-term opportunity to capitalize on structural trends.
SGH’s success also hinges on its ability to adapt to local demand. Its focus on affordable, science-backed supplements—rather than premium or imported products—resonates with Indonesia’s price-sensitive consumers. This model contrasts with Western healthcare plays, where cost is less of a barrier. For PE firms, the key is identifying companies that balance innovation with accessibility, a sweet spot SGH has mastered.
Investment Implications and Strategic Considerations
CVC’s potential exit raises two critical questions for investors:
1. Is the timing right for selling a high-growth asset?
SGH’s 5.5% share price gain in 2025 and robust EBITDA margins suggest it is in a strong position to scale. However, selling at a premium ensures CVC locks in returns before market conditions shift. Given the company’s exposure to Indonesia’s retail and digital health ecosystems, retaining a minority stake could allow CVC to benefit from future growth while mitigating downside risk.
- What does this mean for the broader healthcare sector?
A successful exit would validate the appeal of Southeast Asian healthcare plays to global investors. It could spur further consolidation in the sector, as buyers seek to capture SGH’s distribution network and brand equity. For institutional investors, this signals an opportunity to target similar companies in Vietnam, the Philippines, or Thailand, where healthcare demand is equally robust.
Conclusion: A Win-Win for Investors and the Sector
CVC’s potential stake sale in Soho Global is more than a transaction—it is a testament to the maturation of Southeast Asia’s healthcare sector. For institutional investors, the deal underscores the importance of balancing liquidity needs with long-term value creation. While exiting a high-performing asset may seem counterintuitive, it reflects a disciplined approach to portfolio management in a competitive market.
For those eyeing the region’s healthcare sector, the takeaway is clear: Southeast Asia offers a unique blend of demographic growth, regulatory tailwinds, and underpenetrated markets. As CVC’s exit demonstrates, the key to success lies in identifying companies that not only meet today’s demand but are also positioned to lead tomorrow’s healthcare revolution.
Investment Advice:
– Short-Term: Monitor SGH’s share price and any announcements regarding the stake sale. A successful exit could catalyze investor confidence in Indonesian healthcare stocks.
– Long-Term: Consider adding to Southeast Asian healthcare funds or ETFs, which offer diversified exposure to the region’s growth drivers.
– Due Diligence: Focus on companies with strong EBITDA margins, scalable distribution, and a clear value proposition for price-sensitive consumers.
In an era of global economic uncertainty, Southeast Asia’s healthcare sector remains a beacon of growth—a testament to the power of strategic investing in emerging markets.